GlassScriptPhysician profile
Krishnaveni Bethi
NPI 1821067083
$5,427.94
in general payments reported to CMS, 2019-2025
42 companies · $598 in 2025
The $598 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,819 · 2020: $201 · 2021: $276 · 2022: $152 · 2023: $1,280 · 2024: $1,104 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,980.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $836.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $693.77 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $645.18 | 2019-2025 | |
| Abbott Laboratories | $490.23 | 2019-2025 | Freestyle Libre 3, Eterna |
| Lilly USA, LLC | $373.40 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $285.01 | 2019-2024 | Farxiga, Breztri |
| Astellas Pharma US INC | $250.63 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $202.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $193.52 | 2019-2025 | Ofev, Jardiance |
| Abbvie INC. | $159.74 | 2021-2023 | Vraylar |
| Amgen INC. | $116.97 | 2019-2025 | Otezla, Repatha |
| Allergan, INC. | $103.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $96.55 | 2019-2025 | |
| Eisai INC. | $94.21 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.78 | 2024 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnaveni Bethi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.